Zavabresib (OPN-2853)
Myelofibrosis
Phase 1Active
Key Facts
About Opna Bio
Opna Bio is a private, clinical-stage oncology biotech founded in 2021, leveraging a deep scientific foundation in the Hallmarks of Cancer. The company's strategy centers on designing small molecule inhibitors and degraders with differentiated pharmacokinetic profiles, such as 'pulsatile dosing,' to improve safety and efficacy. Its most advanced assets, the BET inhibitor zavabresib (OPN-2853) and the EP300 inhibitor OPN-6602, are in early-stage clinical trials for myelofibrosis and multiple myeloma, respectively. The leadership team, including co-founder and CSO Gideon Bollag, has a proven track record of advancing multiple drugs to FDA approval.
View full company profileTherapeutic Areas
Other Myelofibrosis Drugs
| Drug | Company | Phase |
|---|---|---|
| Tasquinimod | Active Biotech | Phase Ib/IIa |
| GB2064 | Galecto | Phase 2 |
| Exploratory Program | Cellarity | Pre-clinical |
| Myelofibrosis Program | Sequantrix | Pre-clinical |
| Jakafi (ruxolitinib) | Incyte | Marketed |
| KER-050 (Eltritercept) | Keros Therapeutics | Phase 2 |
| Selinexor | Karyopharm Therapeutics | Phase 3 |